FPT-SOFTWARE
31.7.2024 04:01:26 CEST | Business Wire | Press release
Global leading IT company FPT Software announced that its Chief Artificial Intelligence Officer, Dr. Nguyen Xuan Phong, has been listed on the 2024-2025 Artificial Intelligence 150 (AI150) list by Constellation Research, recognizing leaders pioneering AI transformation efforts around the globe. The Chief AI Officer is the only executive from a Southeast Asian enterprise to be named to this elite list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730156983/en/
(Graphic: Business Wire)
2024-2025 Artificial Intelligence 150 (AI150) is an inaugural initiative by Constellation Research, a technology research and advisory firm based in Silicon Valley and one of the world’s leaders in digital transformation and disruptive technology consulting. The AI150 celebrates top global executives leading AI transformation efforts globally, across multiple industries, and in various roles including Chief AI Officer, Chief Digital Officer, Chief Technology Officer, and Chief Executive Officer.
The selection process lasts six months, from nomination by industry leaders to extensive reference checks for real projects, leadership, mentorship abilities, and standing among colleagues and peer groups. Each leader on the AI150 demonstrates a comprehensive understanding of how the world is responding to artificial intelligence and how new technologies can be leveraged for future innovation.
The accolade is a testament to Dr. Nguyen Xuan Phong and FPT Software’s commitment to being a pioneer, practitioner, and advocate for the acceleration of Intelligence Transformation while using AI to address key business and technology challenges of global enterprises. Others featured in the 2024-2025 list include executives from global technology leaders like SAP, Adobe, Google, Intel, Facebook, and Microsoft, as well as Fortune 500 enterprises such as Ford Motor, United Airlines, TotalEnergies, Merck, and Schneider Electric.
FPT Software and its parent company, FPT Corporation, have over a decade of experience in the research and development of AI solutions since the establishment of its first AI Research Lab in 2019, serving as a comprehensive research, development, and learning facility for 20,000 tech personnel. In his role, Dr. Nguyen Xuan Phong heads a robust global AI Center that drives AI research and industrial application for FPT Software’s global clients, strategizing AI integration, fostering innovation, boosting productivity, and ensuring ethical AI practices. He played an instrumental role in FPT Corporation’s global partnerships with leading AI players such as NVIDIA, Mila, Landing AI, AITOMATIC, and the recent founding membership of the AI Alliance led by IBM and Meta.
“At FPT Software, we believe AI is not just about algorithms; it’s about transforming organizations, industries, and people’s lives. We are committed to expanding our AI ecosystems and embedding AI and Generative AI into all of our solutions and services, as this technology will fundamentally transform everything in business and our society,” said Dr. Nguyen Xuan Phong. “It is my pleasure to be recognized in this esteemed list, and I look forward to engaging with Constellation Research and the AI150 community to participate in global conversations and research studies on AI and business transformation.”
“In the Age of AI, we can expect AI to be infused in every part of the business. This rapidly evolving field has pioneers, policy shapers, and practitioners that will transform industries,” noted R “Ray” Wang, founder and CEO at Constellation Research. “The AI150 is our attempt of identifying a small slice of the innovators and change agents that are making substantial contributions to the advancement of this revolution.”
In addition to his work with FPT Software, Dr. Nguyen Xuan Phong is a decorated scholar with a PhD/EngD from the University of Tokyo, majoring in AI. He also made significant contributions to AI research at Hitachi in Japan and the Mila, Quebec AI Institute in Canada.
The full listing can be found here: Artificial Intelligence 150 2024 - 2025 | Constellation Research Inc.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730156983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom